Establishment of a proper use of ranibizumab for the macular edema in retinal vein occlusion

Establishment of a proper use of ranibizumab for the macular edema in retinal vein occlusion - Establishment of a proper use of ranibizumab for RVO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012188

Enrollment

Registered

2013-11-01

Start date

2013-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Three loading doses of intravitreal injection of ranibizumab at monthly interval followed by PRN A single dose of intravitreal injection of ranibizumab followed by PRN

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)40 years of age or older 2)Person can understand the informed consent. 3)Three is vision loss due to macular edema due to retinal vein occlusion. 4)Three is no other eye disease that affects the central vision and visual acuity.

Exclusion criteria

Exclusion criteria: 1) A history of cerebral hemorrhage and cerebral infection.

Design outcomes

Primary

Measure	Time frame
central retinal thickness visual acuity	—

Countries

Japan

Contacts

Public ContactToshimitsu Ishiguro

Kansai Medical University Departmant of opthalmology

ishigurt@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026